Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The insulin/insulin-like growth factor-1 signalling (IIS) pathway regulates cellular and organismal metabolism and controls the rate of aging. Gain-of-function mutations in p110α, the principal mammalian IIS-responsive isoform of PI 3-kinase (PI3K), promote cancer. In contrast, loss-of-function mutations in p110α impair insulin signalling and cause insulin resistance, inducing a pre-diabetic state. It remains unknown if long-term p110α inactivation induces further metabolic deterioration over time, leading to overt unsustainable pathology. Surprisingly, we find that chronic p110α partial inactivation in mice protects from age-related reduction in insulin sensitivity, glucose tolerance and fat accumulation, and extends the lifespan of male mice. This beneficial effect of p110α inactivation derives in part from a suppressed down-regulation of insulin receptor substrate (IRS) protein levels induced by age-related hyperinsulinemia, and correlates with enhanced insulin-induced Akt signalling in aged p110α-deficient mice. This temporal metabolic plasticity upon p110α inactivation indicates that prolonged PI3K inhibition, as intended in human cancer treatment, might not negatively impact on organismal metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Middle-aged p110αD933/WT mice fed a high fat diet maintain better metabolic profiles than WT littermates. Male mice were fed a high fat diet (45% calories derived from fat) at 66 weeks of age and for 14 weeks and were subsequently metabolically phenotyped as follows: A. Intraperitoneal insulin (2 U/kg) tolerance test (n = 6 per genotype). B. Intraperitoneal glucose (1 g/kg) tolerance tests (n = 6 per genotype). C. Insulin-stimulated Akt phosphorylation. Mice were injected with insulin (0.25 mU/g) via the inferior vena cava and Akt phosphorylation was assessed by quantitative immunoblot analysis in tissue homogenates [liver, gastrocnemius muscle, and white adipose tissue (WAT)]. Each lane represents an individual mouse (n = 4 per genotype). Signal intensity was quantified and data (mean ± standard deviation) are shown in the graphs below the respective blots.](https://figures.cochat.ai/paper-figures/bffee2ff6c0d4e05ad192713b332cf90/long-term-p110-pi3k-inactivation-exerts-a-beneficial-effect-on-metabolism-figure-2.jpg)
![Figure 3 Chronic p110α inhibition promotes IRS-dependent signalling. A. p110α inhibition prevents IRS downregulation induced by chronic insulin treatment in C2C12 myotubes. C2C12 myotubes (cultured in medium with 5.5 mM glucose) were pre-treated for 16 h with insulin (10 nM) in the presence or absence of A66 (2 µM) or TGX-221 (1 µM). Monolayers were then rinsed with phosphate-buffered saline and lysed either directly for detection of IRS and S6K T389 phosphorylation or after 1 h culture in serum-free medium and re-stimulation with insulin (10 nM for 10 min; referred to in the figure as ‘acute insulin’) for detection of Akt T308 phosphorylation. Lysates were processed for immunoblot analysis with the indicated antibodies. Panels have been rearranged for clarity, but they are from the same immunoblots. Signal intensity was quantified and normalized to that of vinculin, used as a loading control in all immunoblots. B. Quantitative data (mean ± standard deviation) from three independent experiments performed as in A. Statistical comparisons were performed with Student's t-test. C. IRS protein levels (mean ± standard deviation) as determined by immunoblot analysis in epididymal fat pads [white adipose tissue (WAT)] and gastrocnemius muscle homogenates of 80 week old male p110αD933A/WT mice and WT littermates (n = 4 per genotype).](https://figures.cochat.ai/paper-figures/11ebe7900d614f948a855a416fff31ba/long-term-p110-pi3k-inactivation-exerts-a-beneficial-effect-on-metabolism-figure-3.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and other models with decreased IIS activity such as mice hypomorphic for the oncogene PI3K or hyperfunctional for the PI3K-antagonistic oncosuppressor PTEN exhibit increased longevity.214,215”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [214]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pten-overexpressing mice, as well as hypomorphic PI3K mice show an increased longevity”
From The Hallmarks of Aging (2013) · cites this paper as Foukas et al., 2013
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · cited 1×
“…activity of the insulin/IGF-1/PI3K pathway has been implicated in the development of metabolic diseases such as type-2 diabetes, and preservation of the activity of this signalling pathway is thought to be essential for glucose and lipid homeostasis in the long term (Engelman et al, 2006).”
Extending Healthy Life Span—From Yeast to Humans
Fontana, L., Partridge, L., & Longo, V. D. (2010) · Science · doi:10.1126/science.1172539 · Cited by 3,023 · cited 2×
“This notion is challenged by the observation that loss-of-function mutations in components of the IIS pathway can reduce biomarkers of aging and extend lifespan in worms, flies and mice (Fontana et al, 2010; Kenyon, 2010).”
Kenyon, C. J. (2010) · Nature · doi:10.1038/nature08980 · Cited by 2,739
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767 · cited 2×
“Gaining this information is important given that PIK3CA , the gene encoding human p110 a , is frequently mutated in cancer and that clinical trials are under way to assess p110 a as a therapeutic target in oncology (Vanhaesebroeck et al, 2010).”
Self-citationTatar, M., Kopelman, A., Epstein, D., Tu, M.-P., Yin, C.-M., & Garofalo, R. S. (2001) · Science · doi:10.1126/science.1057987 · Cited by 1,628
Extension of Life-Span by Loss of CHICO, a Drosophila Insulin Receptor Substrate Protein
Clancy, D. J., Gems, D., Harshman, L. G., Oldham, S., Stocker, H., Hafen, E., Leevers, S. J., & Partridge, L. (2001) · Science · doi:10.1126/science.1057991 · Cited by 1,436
(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356 · cited 1×
“The possible impact of p110 a inactivation on the expression/ activity of FOXO transcription factors, known to have broad metabolic regulatory functions (Accili & Arden, 2004), would also merit further investigation.”
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
Cited by
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
“In line with other mouse models with decreased IIS activity, Pten-overexpressing mice, as well as hypomorphic PI3K mice, show an increased longevity (Foukas et al., 2013; Ortega-Molina et al., 2012).”
BackgroundThe PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“…another example, a genetic screen in C. elegans provided the first clue that PI3K controls metabolism and aging (Dorman et al., 1995; Morris et al., 1996), conclusions that were supported by later studies of the PI3K/mTOR pathway in mice (Foukas et al., 2013; Selman et al., 2009; Wu et al., 2013).”
ResultMeta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Self-citationTargeting PI3K/AKT signaling pathway in obesity
Savova, M. S., Mihaylova, L. V., Tews, D., Wabitsch, M., & Georgiev, M. I. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114244 · Cited by 277
Metadata
- Authors
- Foukas, L. C., Bilanges, B., Bettedi, L., Pearce, W., Ali, K., Sancho, S., Withers, D. J., & Vanhaesebroeck, B.
- Affiliations
- University College London (GB)
- Queen Mary University of London (GB)
- Laboratoire Mouvement Sport Santé (FR)
- Imperial College London (GB)
- Corresponding author
- Foukas, Lazaros C.
- Vanhaesebroeck, Bart
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2013-03-11
- Volume
- 5
- Issue
- 4
- Pages
- 563-571
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC3628103
- OpenAlex
- W2121232254
- Cited by
- 91
- References
- 41
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 6 · 2022: 9 · 2021: 16 · 2020: 10 · 2019: 3 · 2018: 4 · 2017: 10 · 2016: 4 · 2015: 16 · 2014: 4 · 2013: 3
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/3.0/ (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Queen Mary University of London
- Wellcome Trust (098565, 093115/Z/10/Z)
- Cancer Research UK (C23338, C23338/A10200, 15965)
- Diabetes Research and Wellness Foundation
- Royal Society
- Medical Research Council
- Biotechnology and Biological Sciences Research Council (BB/I007806/1, BB/H020527/2)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- PI3K inhibition, aging, lifespan extension, insulin resistance, glucose tolerance, fat deposition, insulin receptor substrate, Akt signaling, hyperinsulinemia, metabolic plasticity, cancer treatment side effects
- MeSH terms
- Animals, Fats, Female, Glucose, Humans, Insulin, Male, Metabolic Diseases, Mice, Inbred C57BL, Time Factors, Mice, Knockout, Gene Silencing, Mice, Insulin Receptor Substrate Proteins, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism. https://app.cochat.ai/papers/10.1002/emmm.201201953
- The paper
- Foukas, L. C., Bilanges, B., Bettedi, L., Pearce, W., Ali, K., Sancho, S., Withers, D. J., & Vanhaesebroeck, B. (2013). Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism. EMBO Molecular Medicine. https://doi.org/10.1002/emmm.201201953
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.